Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JR, Have to agree with you here. Denner and Sarissa 'likely have a lot of influence' on how Amarin is run - but as you said 'Denner is NOT on the board'.
And Hedge Funds works often in 'teams' - no way anyone can say that Sarissa is (not though partners) shorting Amarin - if they valuate that to be the best short term way to do business / make money.
-------------------------
And I am with you all the way - that Sarissa and Denner have 'big long term plans' for Amarin.
I like $10- 15 better than $5. BO announcement will be there some day - 2025 - 26 - not unlikely, if besides UK - a couple of other big countries in EU and possibly China - will start to create noticeable revenue ✌️
Capt, I thought about it a couple of times before sharing facts of our small country (5 mill people).
But in my experience the truth wins in the end.
Hopefully the 'ignorant reasons' given by danish authorities on this matter can be used in places 'that actually maters' for the future og Amarin - and then my little countrys 'experts' will surely have to acknowledge Vascepa/Vazkepa as being one of the most beneficial drugs ever' in keeping a 'good general health long as possible' 😀
Capt,
Tabel 2. Oplysninger om Vazkepa og øvrige lægemidler ud over statiner
Lægemiddel
(handelsnavn) Tilskudsstatus:
Pris per daglig dosis (kr.)* Vazkepa, icosapent ethyl, bløde kapsler - 67,25 kr. [998 mg]
Gemfibrozil, filmovertrukne tabletter/hård ekapsler (Lopid) Generelt klausuleret til patienter
med isoleret svær forhøjelse af triglycerid eller patienter med kombineret hyperlipidæmi evt. i
kombination med statin 2,57-13,58 kr. [300 mg; 600mg]
Ezetimib, tabletter (fx Ezetimibe ”Medical Valley”) Generelt tilskud 0,44-0,85 kr.
[10 mg] * Tilskudspris i takstperioden 1. november 2021 til 14. november 2021.
Capt, Your not correct about Denmark. VAZKEPA is approved but sadly 'no reimbursement'.
Many living in other places of the world - think that 'everything' regarding healt is free in Scandinavia - that is not true at all. Eg you have to pay big part of the bill at the dentist - and also part of 'even reimbursed medicine'.
Under here document (in danish) denying reimbursement of VAZKEPA.
https://laegemiddelstyrelsen.dk/da/tilskud/generelle-tilskud/afgoerelser/~/media/299C9E264F75408DBB14AB855F8A8FDB.ashx
Under here first part of document translated:
Vazkepa does not receive general or generally claused subsidies
Decision
Vazkepa, soft capsules containing icosapentethyl in the strength 998 mg do not get
general or generally claused subsidy.
Case preparation
On 29 June 2021, you applied for a general grant for Vazkepa, soft capsules with
content of icosapentethyl in the strength 998 mg (hereinafter Vazkepa).
Approved indication
Vazkepa is indicated to reduce the risk of cardiovascular events in
adult statin-treated patients at high cardiovascular risk with elevated
triglyceride values ??(= 150 mg/dl [= 1.7 mmol/l]) and
• diagnosed cardiovascular disease or
• diabetes and at least one other cardiovascular risk factor.1
Delivery group
Vazkepa is placed in extradition group B
Denisk, How much proof do you need - unless you say Amarin are lying - 'very publicly here' !
https://finance.yahoo.com/news/amarin-receives-national-reimbursement-vazkepa-201500835.html
Capt, Thanks for response. I'll dig into the links you provided a bit later (wife after me for spending to much time with the computer) 🙂
But glad you think 'there is hope - in having the science be noticed' - even the gigantic FO OTC industri is spreading information - that would fit very closely to the truth' for Vascepa' - not even 'in the same State' for prescription drug Lovaza - which could instead actually improve your risk of CDV problems !
-------------------------------
And look here - how Lovaza is presented to the public - as a Life Saver drug - with no health authorities (like FDA) interfering !
https://lovaza.com/
Capt, From where does most people get their knowledge (questions answered) these days: GOOGLE.
------------------------
Look what happens if i ask Google: 'omega 3 fish oil benefits'
Omega 3 lowers blood pressure, reduces triglycerides in the blood, helps reduce joint inflammation in rheumatoid disease, helps nourish brain and eyes functions, helps prevent and alleviate dementia, depression, asthma, migraine, and diabetes, and helps reduce the risk and preventing heart disease and ischemic stroke.7. jun. 2023
Nuke,
NTB, ANNE GRETE STORVIK
5 July 2024 at 08:36
The Ministry of Health and Care cancels the refusal from the Directorate for Medical Products in the processing of pre-approved reimbursement for the medicine Vazkepa (icosapentetyl).
"We have come to the conclusion that DMP has not had a good enough case management. As a consequence of this, we have come to the conclusion that the decision on refusal of pre-approved reimbursement is invalid, and must therefore be revoked", writes the Ministry of Health and Care to VG.
The case concerns the Directorate for Medical Products' (DMP) treatment of whether pre-approved reimbursement should be granted for the heart medicine Vazkepa, which means that it can be prescribed on a blue prescription.
The processing of such cases should take a maximum of 180 days, but the DMP took 614 days to process the case, which ended in a decision to reject it.
The pharmaceutical company Amarin, which markets the drug, appealed against the decision in September last year. They believed that the directorate had not made a real assessment of the complaint, that the wrong proof requirements had been used, and that they were exposed to unfair discrimination.
Unit leader Anette Grøvan in the DMP clarifies that the decision has been revoked, not overturned, and that it will now be processed again in the DMP.
The medicine has had marketing authorization in Norway since March 2021.
Sleven, That is good news - (hopefully - will be noticed also in Denmark):
We are only ½ way there though - but a least the chance of reimbursement ought to have good ods after Amarin complaint taken serious.
Enhetsleder Anette Grøvan i DMP presiserer at vedtaket er opphevet, ikke omgjort, og at den nå skal til ny behandling i DMP.
Lizzy, If you take the official announcement from Amarin for what it says - the org deal should be intact.
https://finance.yahoo.com/news/amarin-partner-eddingpharm-receives-regulatory-113000810.html
Under the partnership agreement, EDDING is responsible for development and commercialization activities in the China territory and associated expenses. Amarin provides development assistance and is responsible for supplying finished bulk product. Based upon the NMPA approval for the CVRR indication, Amarin will earn a regulatory milestone payment in the amount of $15 million. EDDING will also pay Amarin tiered double-digit percentage royalties on net sales of VASCEPA in the territory. Amarin will supply product to EDDING under negotiated supply terms.
Zip - Rose, Ok - understand the calculations. Still a lot of Chinese potential prescriptions - Thanks 😀
Zip, I dont know from were you have China population size - but I think it is rather to low 🙂
https://www.worldometers.info/world-population/china-population/
JR, That was all that my org. question to you was about - you confirming what you yourself suggested - at copy/paste - the Confirming mail from Brave research group here. I simply were interested to see the formulation in that letter - as this subject has been debated a lot here 'earlier.
---------------------------------------------------
Then Sleven comes out aggressively attacking that I asked a simple question - do anyone know where Amarin stands in the delisting process (being under $1- for now some time). Why that coursed - for this 'nonsense debate' who knows.
This self important guy sure has a short fuse - in his often provoking behavere.
Sleven, And you should likewise be embarrassed for starting 'the non factual' rumor 'Brave did not meet endpoint' - right.
I guess that it why you 'out of the blue' starts attacking people - as so often before.
Sleven, You bloated again - as so often before. This has nothing to do with you what so ever (beside - as I recall you actually started the rumor 'Brave not successful' - and ended being very offended 'on everyone' ).
--------------------------
Post were for JR - offering the other day 'to place his mail here - with Brave researchers saying endpoint not met' - shouldn't be that hard to understand with your sharp sense of logic.
JR, You promised couple of days ago to 'show mail proof' - of your korrespondance with responsible researchers behind the BRAVE study - that the study didn't meet the endpoints.
-------------------------
Haven't seen that response / proof for your 'talking Brave results down' - before the results are even published ?
Please - copy the mail in question here - for all to see - as you yourself surgested !!!
Whala, Thanks - your answer here 'actually comforting' - as far as 'the delisting goes' - as I read it !
------------------------
There is still time for Amarin - to regain trust in the future - second ½ of 2024. Taking SP above $1 would be good for a start - before to long ✌️
Whala, The bigger the 'Pump' - the better - as long as what spoken is the truth. Wee need all the help we can get right now !
-----------------------------
Anyone know 'how long to delisting' - has warning been given 'again' ?
North, Talking Ozempic - did you see the interview below ?
https://tuckercarlson.com/the-case-against-ozempic
liamlinden, Up $128k - did you sell then ? 🙂
Irish, Think you might just be right here.
-----------------------------------
Remember - some weeks back - he spins a story of 'his wife working from home' - him "accidently overhearing" - a talk with a patient of his wife - with no luck trying to defend the 'price for Vascepa' compared to a Statin.
His 'usual' - every chance placing needles in the confidence and trust in Amarin and Vascepa - this 'imaginary patient conference of his wife' - a little over the top in spinning - for anyone on this board to believe !
Whala, Will this be aloud to stand - as a result of the 2020- 21 World wide virus attack.
--------------------------------
Juli 4. coming up - a great tribute to your big Country - of combined very different States 🙂
JR, Every pro Day Trader 'Shorts' - every pro HF 'Shorts' - it is part of the game in the HF finance money world - given where Amarin stock is' at the moment.
------------------------------
What is important to remember here is - that a HF like Sarissara can/could invest 'in whatever stock in the marked - and 'Short' - if they felt it were 'best investment plan.
------------------------------
This is NOT what Sarissa and Denner have done around Amarin. There is clearly a long term strategy and plan - in using the effort and energy in taking on KM and 'old board' in the Proxy fight.
Truth is' where Amarin are' after the Du-disaster' (opening the door for FREE - for every aggressive generic company) - we couldn't have hoped for a better situation - than Sarissa and Denner taking over.
Lemm, Get your point. Honestly haven't followed the case very close.
You say its 'not about the fraudulent killed 6 patents' - but about infringement frem generics - on FDA CDV approval 2019.
And you are of course right - even it all started with the patents being disqualified - from 'not a chemist' - not a scientist - not a specialist in Bio.
Amarin were killed (not dead though) - by a populist liberal female judge - who really had no idea about the value of VASCEPA and the +10-year research by specialists - which she shoots down and undermines in seconds.
north, You have been a patent lawyer for 55 years - what I have heard. Legal stuff for me in the same period - i honestly know close to nothing about locally - even less in complex legal systems in the many states of America.
---------------------------
From your answer - I understand that in fact - an extension of patent period has happened in the Courts of US - even way back in time.
SP of AMRN after the current positive legal announcement shows' - that this is not 'in itself' something - that will blow Amarin out of the water bigtime'.
But still 'an important opening' for a change in the US - that has the potential of being significant in the not to far future :)
Marjac, As always - thanks for your pro evaluation of the legal situation at hand - which I hear you say - 'is the best it has been since the fatal blow in Nevada marts 2020'.
Talking best case - has there ever been a patent case in USA - where patents were reinstated and prolonged (say to 2035) as a compensation for the patent-years lost - as result of an earlier ruling based on fraud ?
DCM8, Very impressive market research - looking at icosapent ethyl (EPA) . Thanks !
ProLiberty, Agreed in headlines of your constructive thinking.
What we all have to remember is that Sarissa is a very experienced HF - that is in every way in known terrority with undervalued Bio company Amarin - which is exactly what Denner have specialized in.
As you point out - they knew that generics would move in on Amarin revenu when they entered - but given big cash holding and no debt - reducing cost everyway possibly - they would gain the necessary time to recover - and from there go for the end goal - BO to a big Pharma Company.
Advise - newer mention Trump to Whala - as you saw - He Shortens 🙂
BBI, Looking at financials for Amarin at Nasdaq is no fun experience. Profit falling all the way.
Why I bring it here anyway - is that it actually in only two numbers - looking left - scrolling to the bottom of page - shows precisely your point about the KM leadership - and the current Sarissa / Denner period after the Proxy.
Even profits has fallen dramatically in pressure from generics - the negative net income has been brought down to half. It does give hope for the future - even headwinds are many.
https://www.nasdaq.com/market-activity/stocks/amrn/financials
------------------------------
Sales, General and Admin.
23 $199,938
22 $304,416
21 $408,334
20 $463,312
MA52TA, Whala - again' - and again' expose himself as 'doing everything to talk opportunitets and value of Amarin DOWN' - much as possible.
---------------------------
Plus 20.000 posts - No AMRN shares ????
Why number of posters think he is indeed Dr. MO Nissen !
The legal cases started by Amarin - and against Amarin are debated a lot on the board.
A good place for to find some 'cooked down' knowledge of what it is all about - is the site below:
First the latest summery from April 17. 2024
https://fedcircuitblog.com/2024/04/17/argument-recap-amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
Under here - total list of Amarin related articles:
https://fedcircuitblog.com/?s=Amarin&data=all
What effect are you seeing from your efforts to stop naked short selling of your stock?
o
We’ve contacted various authorities, and they’re taking a closer look at the issue. We were on the Nasdaq Reg SHO threshold list for months, which indicates unusual trading activity, and the rate of failures to deliver on our stock has been abnormal. If this is what it appears to be—illegal naked short selling—then the perpetrators need to be criminally prosecuted, possibly using federal and state RICO statutes. If there’s illegal trading, then the problem will continue until those responsible are held to account.
Fair enough - ORBA' - we all want the same here - for this Company and its' stock to recover !
-----------------------------
A number of posters here - just need to remind themselves (now and then):
Only reason Sarissa and Denner is here is' - Du Disaster ruling - which in 'seconds' made AMRN - what Denner and his crew considers 'an undervalued Bio Stock (what they specializes in).
Had things gone as JT expected (when on CNBC (with + $23 on the wall) - no one here would have ever heard of Sarissa.
So you support - FSS - 'Amarin is sinking' - in his 'earth is ending thinking' - or how to read these negative 'copy pastes' ?
-----------------------------------------------
1. For a small Bio Company to have over 300 mil dollar in cash - that means 'you are not dead'. l
2. Amarin VAZKEPA holds 15 years still of patents in Europe - which is an eternity in this Bio game.
3. And maybe most important: Amarin Brand VASCEPA - is likely the most important Drug ever developed - in helping people avoiding a long line of the worst devastating deceases know to man.
---------------------------------------
The challenge is getting one of the big powerful Big Pharmas to understand the potential here. When that happens -VASCEPA / VAZKEPA can / will be a gigantic succes WW in making people of adge have a better' more healthy' - and longer' life 🙂
Ok - 'boring weekend' - so lets play a little🙂
Nah... I hate to break it to you, but when a microcap stock named AMRN makes your house POOF! disappear,... now THAT is wizardry in a land where PRICE IS KING!!
FSS, Is as phony as it gets on these anonymous boards.
------------------------------------------
The guy is 'all over the place' in his wild fantasy projections.
How any one can take this guy serious - 'in the world of facts' and reality' is a continued mystery !
----------------------------
It just again' again' shows - that humans have always been drawn to 'wizards and mysterious truth tellers' - even 100% lack of connection to reality 🙃
exwannabe, What started this debate were Whala saying 'US market is lost' !
The Other day - in another debate on 'what is actually the difference for insurers - in prise - generics - Brand - Whala informed - generics $ 310 - Brand 390.
That difference does not seem that big a mountain to climb - for Amarin - going AG.
Keyword going forward is Volume. Number of prescriptions has to rise - and every means available (including possibly adverting again) must be used to regain/expand US market.
Whala,
Personally I think the US is lost
Serve333, A new 'promising' EPA based product in Phase 3 of trial (where most BO's are made) - wouldn't hurt Amarins (Denner's) chance of making a good deal with one of the major BP's - in say next couple of years.
That there are no new' trials - is no proof that Amarin - are not working on developing new products - it could be 'that they are just not ready for testing yet'.